A US-based KOL covers treatment options across various lines of therapy and quality of life changes in early and advanced stage patients. This interview also covers an assessment of the current therapy pipeline, novel targets in ovarian cancer and reimbursement issues faced by patients.

This interview was conducted on April 25, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.